These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 503884)

  • 21. [Hyperlipoproteinemia in diabetes mellitus].
    Slavina LS; Mazovetskiĭ AG; Negovskaia AV; Romanovskaia GA
    Probl Endokrinol (Mosk); 1981; 27(1):36-9. PubMed ID: 7232348
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Effect of omega-3-fatty acids on lipoprotein metabolism. Different effects in various phenotypes].
    Singer P; Hüve J
    Fortschr Med; 1991 Aug; 109(24):476-9. PubMed ID: 1937329
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hemorrheologic abnormalities in defined primary dyslipoproteinemias with both high and low atherosclerotic risks.
    Otto C; Ritter MM; Richter WO; Minkenberg R; Schwandt P
    Metabolism; 2001 Feb; 50(2):166-70. PubMed ID: 11229424
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Primary hyperlipoproteinemias. Clinical, biological and physiopathological aspects].
    Bakir R; Chanu B; Rouffy J
    Pathol Biol (Paris); 1983 Apr; 31(4):248-58. PubMed ID: 6346238
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Blood coagulation and fibrinolysis systems in primary hyperlipoproteinemias].
    Berent H; Uchman B
    Pol Arch Med Wewn; 1983 Sep; 70(3):131-4. PubMed ID: 6657492
    [No Abstract]   [Full Text] [Related]  

  • 26. [Hyperlipoprotein phenotypes as risk factors in ischemic cardiopathy. II. Clinical aspects].
    Walter-Rosianu A
    Rev Pediatr Obstet Ginecol Pediatr; 1984; 33(2):145-60. PubMed ID: 6429817
    [No Abstract]   [Full Text] [Related]  

  • 27. Distribution of actin, myosin and actin binding protein in platelets of patients with hyperlipoproteinemia.
    Eldor A; Kahane I; Yatziv S; Fainaru M; Muhlrad A
    Thromb Res; 1983 Jul; 31(1):155-62. PubMed ID: 6612694
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [The therapeutic efficacy of bezafibrate in hyperlipoproteinemias of various types].
    Noseda G; Fragiacomo C; Weidmann P; Bachmann C
    Schweiz Med Wochenschr; 1980 Dec; 110(49):1875-7. PubMed ID: 7455660
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Clinical aspects of hyperlipoproteinemia (author's transl)].
    Kaffarnik H; Schneider J
    Ther Umsch; 1980 Nov; 37(11):973-9. PubMed ID: 7455962
    [No Abstract]   [Full Text] [Related]  

  • 30. [Gemfibrozil in the treatment of hyperlipoproteinemias].
    Monova D; Petrova V; Belovezhdov N
    Vutr Boles; 1991; 30(2):56-8. PubMed ID: 1891900
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of heparin-induced lipolysis on the distribution of apolipoprotein e among lipoprotein subclasses. Studies with patients deficient in hepatic triglyceride lipase and lipoprotein lipase.
    Rubinstein A; Gibson JC; Paterniti JR; Kakis G; Little A; Ginsberg HN; Brown WV
    J Clin Invest; 1985 Feb; 75(2):710-21. PubMed ID: 3973025
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Phenotype change in hyperlipoproteinemias].
    Meincke H
    Dtsch Z Verdau Stoffwechselkr; 1985; 45(5):236-9. PubMed ID: 4085393
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Recent trend in the research of hyperlipidemia in Japan. Treatment of refractory hyperlipidemia].
    Saito Y; Yoshida S
    Nihon Naika Gakkai Zasshi; 1989 Oct; 78(10):1416-9. PubMed ID: 2513364
    [No Abstract]   [Full Text] [Related]  

  • 34. [Insulinemia in patients with hyperlipoproteinemia type IIa and V].
    Młyński J
    Kardiol Pol; 1981; 24(9):605-9. PubMed ID: 7029111
    [No Abstract]   [Full Text] [Related]  

  • 35. [Biochemical diagnosis of hereditary hyperlipoproteinemias].
    Tvorogova MG; Rozhkova TA; Alidzhanova KhG; Semenova OA; Sobolev AV; Kukharchuk VV; Titov VN
    Ter Arkh; 1998; 70(4):9-15. PubMed ID: 9612894
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Hyperlipoproteinemias].
    Chanu B
    Soins; 1987 Jul; (502):7-12. PubMed ID: 3672160
    [No Abstract]   [Full Text] [Related]  

  • 37. [Primary hyperlipoproteinemia in its clinical and laboratory aspects. IV. Blood coagulation and fibrinolysis indicators].
    Borodin M; Jurek D; Gregorczyk J; Pieczul-Mróz J; Cwajda H
    Przegl Lek; 1983; 40(10):727-32. PubMed ID: 6665208
    [No Abstract]   [Full Text] [Related]  

  • 38. [Arteriosclerosis. III. Laboratory diagnosis of dyslipoproteinemia].
    Nowicka G; Kłosiewicz-Latoszek L
    Wiad Lek; 1985 Aug; 38(16):1179-84. PubMed ID: 4082589
    [No Abstract]   [Full Text] [Related]  

  • 39. [Subfractions of HDL cholesterol. Occurrence in hyperlipoproteinemia type IIa and IV].
    Mertz DP; Thuilot G; Bürvenich K
    Fortschr Med; 1986 Jul; 104(26):508-10. PubMed ID: 3744260
    [No Abstract]   [Full Text] [Related]  

  • 40. [Cholesterol and triglyceride plasma levels in patients with primary hyperlipoproteinemia. Decline after short-term i.v. glucagon administration].
    Andĕl M; Brodan V; Kucerová L; Grafnetter D; Kuhn E; Veselková A
    Cas Lek Cesk; 1980 May; 119(22):616-21. PubMed ID: 7427980
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.